The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Keytruda Qlex
pembrolizumab and berahyaluronidase alfa-pmph · PEMBROLIZUMAB 165 mg/mL; BERAHYALURONIDASE ALFA 2000 U/mL · Injection, Solution · Subcutaneous · Merck Sharp & Dohme LLC
NDC 00006-3083-01 · 1 VIAL in 1 CARTON / 2.4 mL in 1 VIAL · BLA · View full market →
One drug, every price
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
ⓘ How this was built
Data sources
- CMS NADAC (pharmacy acquisition, weekly)
- CMS Part B ASP quarterly payment limits
- CMS Maximum Fair Prices (IRA negotiated, NDC-level)
- Medicare Part D Spending by Drug (data.cms.gov, name-matched)
- VA FSS / Big4 federal contract prices (va.gov, twice monthly)
- ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
- California SB-17 WAC filings (list price, per package)
Method
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
- Medicare Part B pays (ASP+6%)$31.94per billing unit (1 MG)HCPCS J9277 · Jul 1, 2026
- Federal ceiling (Big4)$9,080.69per unitMerck Sharp & Dohme LLC · Mar 1, 2026
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$12,031.36
Reported to Texas DSHS · 2026 annual filing · Merck Sharp & Dohme LLC
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicare Part B (ASP)
Payment limit per 1 MG
$31.940
HCPCS J9277 · Jul 1, 2026 quarter · typically ASP + 6%
Medicaid spend (2026 YTD · Q1)ⓘ
$182,363
16 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Is this a "specialty" drug?
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- BLA761467
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of pembrolizumab and berahyaluronidase alfa-pmph (Injection, Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Merck Sharp & Dohme LLC | PEMBROLIZUMAB 165 mg/mL; BERAHYALURONIDASE ALFA 2000 U/mL | Aug 26, 2026 | Aug 31, 2026 |
| Merck Sharp & Dohme LLC | PEMBROLIZUMAB 2000 U/mL; BERAHYALURONIDASE ALFA 165 mg/mL | Jul 22, 2026 | Aug 21, 2026 |
| Merck Sharp & Dohme LLC | BERAHYALURONIDASE ALFA 2000 U/mL; PEMBROLIZUMAB 165 mg/mL | Jul 15, 2026 | Jul 19, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Keytruda Qlex — NDC 00006-3083-01," retrieved September 3, 2026, https://drugdashboards.com/drug/00006308301.
Free to cite with attribution — see how the data is put together.